Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, et al. Neuroblastoma. Nature Reviews Disease Primers. 2016;2(1). doi: https://doi.org/10.1038/nrdp.2016.78.

Salvá RN, Franco MP, Saurí AR, Llombart-Bosch A, Sánchez VC, Fos SN. Genomic profile in high risk neuroblastoma by comparative genomic hybridization. An Pediatr (Barc). 2006;64(5):449–56. doi: https://doi.org/10.1157/13087872.

Article  Google Scholar 

Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol. 1999;17(7):2264–79. doi: https://doi.org/10.1200/JCO.1999.17.7.2264.

Article  CAS  PubMed  Google Scholar 

Spitz R, Hero B, Skowron M, Ernestus K, Berthold F. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification. European Journal of Cancer. 2004;40(18):2753–9. doi: https://doi.org/10.1016/j.ejca.2004.05.002.

Article  CAS  PubMed  Google Scholar 

Szewczyk K, Wieczorek A, Młynarski W, Janczar S, Woszczyk M, Gamrot Z, et al. Unfavorable Outcome of Neuroblastoma in Patients With 2p Gain. Frontiers in Oncology. 2019;9. doi: https://doi.org/10.3389/fonc.2019.01018.

Jeison M, Ash S, Halevy-Berko G, Mardoukh J, Luria D, Avigad S, et al. 2p24 Gain Region Harboring MYCN Gene Compared with MYCN Amplified and Nonamplified Neuroblastoma. The American Journal of Pathology. 2010;176(6):2616–25. doi: https://doi.org/10.2353/ajpath.2010.090624.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Campbell K, Gastier-Foster JM, Mann M, Naranjo AH, Van Ryn C, Bagatell R, et al. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children’s Oncology Group. Cancer. 2017;123(21):4224–35. doi: https://doi.org/10.1002/cncr.30873.

Article  CAS  PubMed  Google Scholar 

Tajiri T, Shono K, Tanaka S, Suita S. Evaluation of genetic heterogeneity in neuroblastoma. Surgery. 2002;131(1):S283-S7. doi: https://doi.org/10.1067/msy.2002.119964.

Article  Google Scholar 

Liu J, Ren Q, Xiao H, Li S, Zheng L, Yang X, et al. Whole-tumoral metabolic heterogeneity in 18F-FDG PET/CT is a novel prognostic marker for neuroblastoma. Cancer Imaging. 2024;24(1). doi: https://doi.org/10.1186/s40644-024-00718-3.

Liu J, Si Y, Zhou Z, Yang X, Li C, Qian L, et al. The prognostic value of 18F-FDG PET/CT intra-tumoural metabolic heterogeneity in pretreatment neuroblastoma patients. Cancer Imaging. 2022;22(1). doi: https://doi.org/10.1186/s40644-022-00472-4.

Mueller WP, Coppenrath E, Pfluger T. Nuclear medicine and multimodality imaging of pediatric neuroblastoma. Pediatric Radiology. 2012;43(4):418–27. doi: https://doi.org/10.1007/s00247-012-2512-1.

Article  PubMed  Google Scholar 

T Pflüger, I Schmid, E Coppenrath, Weiss M. Modern nuclear medicine evaluation of neuroblastoma. Q J Nucl Med Mol Imaging. 2010;54(4):389–400. doi: PMID: 20823807.

Piccardo A, Treglia G, Fiz F, Bar-Sever Z, Bottoni G, Biassoni L, et al. The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy. European Journal of Nuclear Medicine and Molecular Imaging. 2023;51(3):756–67. doi: https://doi.org/10.1007/s00259-023-06486-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Samim A, Tytgat GAM, Bleeker G, Wenker STM, Chatalic KLS, Poot AJ, et al. Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments. Journal of Personalized Medicine. 2021;11(4). doi: https://doi.org/10.3390/jpm11040270.

Higuchi T, Klimek K, Groener D, Chen X, Werner RA. Norepinephrine Transporter–Targeted Cancer Theranostics—New Horizons. Clinical Nuclear Medicine. 2024. doi: https://doi.org/10.1097/rlu.0000000000005567.

Article  PubMed  Google Scholar 

Xia J, Zhang H, Hu Q, Liu S-y, Zhang L-q, Zhang A, et al. Comparison of diagnosing and staging accuracy of PET (CT) and MIBG on patients with neuroblastoma: Systemic review and meta-analysis. Current Medical Science. 2017;37(5):649–60. doi: https://doi.org/10.1007/s11596-017-1785-x.

Article  Google Scholar 

Rufini V, Calcagni ML, Baum RP. Imaging of Neuroendocrine Tumors. Seminars in Nuclear Medicine. 2006;36(3):228–47. doi: https://doi.org/10.1053/j.semnuclmed.2006.03.007.

Article  PubMed  Google Scholar 

Agüloğlu N, Aksu A, Unat DS, Akyol M. The prognostic relationship of 18F-FDG PET/CT metabolic and volumetric parameters in metastatic ALK + NSCLC. Nuclear Medicine Communications. 2022;43(12):1217–24. doi: https://doi.org/10.1097/mnm.0000000000001625.

Article  PubMed  Google Scholar 

Park JS, Lee N, Beom SH, Kim HS, Lee C-k, Rha SY, et al. The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status. Gastric Cancer. 2017;21(2):213–24. doi: https://doi.org/10.1007/s10120-017-0739-0.

Article  CAS  PubMed  Google Scholar 

Li S, Liu J, Wang G, Feng L, Yang X, Kan Y, et al. Predictive value of 2-deoxy-2-fluorine-18-fluoro-D-glucose positron emission tomography/computed tomography parameters for MYCN amplification in high-risk neuroblastoma. European Journal of Radiology. 2024;170. doi: https://doi.org/10.1016/j.ejrad.2023.111243.

Suzuki H, Villamón E, Berbegall AP, Piqueras M, Tadeo I, Castel V, et al. Genetic Instability and Intratumoral Heterogeneity in Neuroblastoma with MYCN Amplification Plus 11q Deletion. PLoS ONE. 2013;8(1). doi: https://doi.org/10.1371/journal.pone.0053740.

Noguera R, Cañete A, Pellín A, Ruiz A, Tasso M, Navarro S, et al. MYCN gain and MYCN amplification in a stage 4S neuroblastoma. Cancer Genet Cytogenet. 2003;140(2):157–61. doi: https://doi.org/10.1016/s0165-4608(02)00677-5.

Article  CAS  PubMed  Google Scholar 

Theissen J, Boensch M, Spitz R, Betts D, Stegmaier S, Christiansen H, et al. Heterogeneity of the MYCN Oncogene in Neuroblastoma. Clinical Cancer Research. 2009;15(6):2085–90. doi: https://doi.org/10.1158/1078-0432.Ccr-08-1648.

Article  CAS  PubMed  Google Scholar 

Squire J, Thorner P, Marrano P, Parkinson D, Ng Y, Gerrie B, et al. Identification of MYCN Copy Number Heterogeneity by Direct FISH Analysis of Neuroblastoma Preparations. Mol Diagn. 1996;1(4):281–9. doi: https://doi.org/10.1054/MODI00100281.

Article  CAS  PubMed  Google Scholar 

Qian L-D, Zhang S-X, Li S-Q, Feng L-J, Zhou Z-A, Liu J, et al. Predicting MYCN amplification in paediatric neuroblastoma: development and validation of a 18F-FDG PET/CT-based radiomics signature. Insights into Imaging. 2023;14(1). doi: https://doi.org/10.1186/s13244-023-01493-8.

Qian L-D, Zhou Z-A, Li S-Q, Liu J, Zhang S-X, Ren J-L, et al. 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) imaging of pediatric neuroblastoma: a multi-omics parameters method to predict MYCN copy number category. Quantitative Imaging in Medicine and Surgery. 2024;14(4):3131–45. doi: https://doi.org/10.21037/qims-23-494.

Article  PubMed  PubMed Central  Google Scholar 

Feng L, Qian L, Yang S, Ren Q, Zhang S, Qin H, et al. Clinical parameters combined with radiomics features of PET/CT can predict recurrence in patients with high-risk pediatric neuroblastoma. BMC Medical Imaging. 2022;22(1). doi: https://doi.org/10.1186/s12880-022-00828-z.

Lee JW, Cho A, Yun M, Lee JD, Lyu CJ, Kang WJ. Prognostic value of pretreatment FDG PET in pediatric neuroblastoma. European Journal of Radiology. 2015;84(12):2633–9. doi: https://doi.org/10.1016/j.ejrad.2015.09.027.

Article  PubMed  Google Scholar 

Ambros IM, Benard J, Boavida M, Bown N, Caron H, Combaret V, et al. Quality Assessment of Genetic Markers Used for Therapy Stratification. Journal of Clinical Oncology. 2003;21(11):2077–84. doi: https://doi.org/10.1200/jco.2003.03.025.

Article  CAS  PubMed  Google Scholar 

Qiang Z, Yeming W, Huanmin W. Expert consensus on diagnosing and treating of neuroblastoma in children: CCCG-NB-2021 Regimen. Chin J Pediatr Surg. 2022;43(7):588–98. doi: https://doi.org/10.3760/cma.j.cn421158-20211227-00638.

Article  Google Scholar 

Koshy A, Jain R, Srinivasan R, Bhatia P, Kakkar N, Rajwanshi A, et al. Cytopathological spectrum of peripheral neuroblastic tumours in fine needle aspiration cytology and categorisation as per International Neuroblastoma Pathology Classification. Cytopathology. 2019;30(6):634–43. doi: https://doi.org/10.1111/cyt.12747.

Article  PubMed  Google Scholar 

Shimada H, Ambros IM, Dehner LP, Hata J-i, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors. Cancer. 1999;86(2):349–63. doi: https://doi.org/10.1002/(sici)1097-0142(19990715)86:2%3C349::Aid-cncr20%3E3.0.Co;2-y.

Article  CAS  PubMed  Google Scholar 

Lonergan GJ, Schwab CM, Suarez ES, Carlson CL. Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation. Radiographics. 2002;22(4):911–34. doi: https://doi.org/10.1148/radiographics.22.4.g02jl15911.

Article  PubMed  Google Scholar 

Wang M, Zhou C, Cai R, Li Y, Gong L. Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients. Diagn Pathol. 2013;8:5. doi: https://doi.org/10.1186/1746-1596-8-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Valent A, Le Roux G, Barrois M, Terrier-Lacombe MJ, Valteau‐Couanet D, Léon B, et al. MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification. The Journal of Pathology. 2002;198(4):495–501. doi: https://doi.org/10.1002/path.1244.

Article  CAS  PubMed  Google Scholar 

Kuzyk A, Booth S, Righolt C, Mathur S, Gartner J, Mai S. MYCNoverexpression is associated with unbalanced copy number gain, altered nuclear location, and overexpression of chromosome arm 17q genes in neuroblastoma tumors and cell lines. Genes, Chromosomes and Cancer. 2015;54(10):616–28. doi: https://doi.org/10.1002/gcc.22273.

Article  CAS